This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Natural history

Authoring team

Knowledge of the natural history of arterial claudication enables the condition to be managed optimally.

Of those that present with intermittent claudication:

  • one third undergo spontaneous remission of symptoms within two years, without any treatment

  • one third remain symptomatically stable

  • one third deteriorate, either becoming severely disabled by restriction of walking ability or developing symptoms of more severe ischaemia such as rest pain

Untreated, about 10% of all patients would progress to necrosis and amputation. Abstinence from smoking greatly improves outcome. The development of collaterals is attributed to the cessation of symptoms in those patients who improve.

The life expectancy of claudicants is approximately 10 years less than that of other individuals of the same age. Their 5-year, 10-year and 15-year mortality rates from the time of presentation are 30%, 50% and 70% respectively. Most die from other manifestations of atherosclerosis such as ischaemic heart disease or stroke.

 

Reference.

  1. Lower limb peripheral arterial disease. NICE Clinical Guideline (August 2012, updated December 2020)

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.